ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: To be more specific, due to the limited option on BCR-ABL junction sequence in CML patients, it will be difficult to design specific and effective sgRNAs with appropriate PAM (NGG) sequence for CRISPR/Cas9 based personalized medicine.